These findings support the hypothesis that combinatorial approaches can re-engage silenced tumour-suppressor pathways in lymphoma cells, offering potential therapeutic relevance in contexts where p53 signalling is functionally suppressed but not genetically deleted. The gene discussed is TP53; the disease is lymphoma.